merkley's questions. senator merkley's questions. you know, one of the things that we need to do is get a process for generics where we give advice to complicated generics before they come in and send in an application. that's what we negotiate under the prescription drug user fee act for the new drugs. and that's something that there's great interest in. and having a program so that for these complicated things, it isn't just a pill, we can interact with companies and give them advice and tell them what to do. so both this workload -- let's not call it a backload, but our large workload we have now, part of which is inherited from the things that are cycling multiple times, is on everyone's mind. and it's definitely part of our discussions is how to deal with that. >> can you report anything about the status of those negotiations, or is that beyond your -- >> i can say, with the industry, they've concluded, and, obviously, there are many other steps. we'd have to have a public meeting as described in a statute and, of course, we'll